Colorectal cancer screening and surveillance: Clinical guidelines and rationale - Update based on new evidence

Gastroenterology

Volumn 124, Issue 2, 2003, Pages 544-560

  Winawer, Sidney ^a,l   Fletcher, Robert ^e   Rex, Douglas ^k   Bond, John ^c   Burt, Randall ^b   Ferrucci, Joseph ^d   Ganiats, Theodore ^f   Levin, Theodore ⁱ   Woolf, Steven ^m   Johnson, David ^g   Kirk, Lynne ^h   Litin, Scott ^j   Simmang, Clifford ^g  

^a AGA National Office   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Eastern Virginia School of Medicine   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ KAISER PERMANENTE MEDICAL CENTER   (United States)

^j MAYO CLINIC   (United States)

^k INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; BARIUM ENEMA; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; CROHN DISEASE; DNA DETERMINATION; DOUBLE CONTRAST RADIOGRAPHY; FAMILIAL COLON POLYPOSIS; FAMILY HISTORY; FECES ANALYSIS; HIGH RISK POPULATION; HUMAN; OCCULT BLOOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SIGMOIDOSCOPY; ULCERATIVE COLITIS;

EID: 0037310758     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2003.50044     Document Type: Review

References (102)

1. Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
2. Smith RA, von Eschenbach AC, Wender R, Levin B, Byers T, Rothenberger D, et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001 - testing for early lung cancer detection. CA Cancer J Clin 2001;51:38-75.
3. U.S. Preventive Services Task Force. Screening for colorectal cancer: recommendation and rationale. Ann Intern Med 2002;137:129-131.
4. Rex DK, Johnson DA, Lieberman DA, Burt RW, Sonnenberg A. Colorectal cancer prevention 2000: screening recommendations of the American College of Gastroenterology. American College of Gastroenterology. Am J Gastroenterol 2000;95:868-877.
5. Simmang CL, Senatore P, Lowry A, Hicks T, Burnstein M, Dentsman F, et al. Practice parameters for detection of colorectal neoplasms. The Standards Committee. The American Society of Colon and Rectal Surgeons. Dis Colon Rectum 1999;42:1123-1129.
6. MMWR. Trends in screening for colorectal cancer: United States, 1997 and 1999. Mor Mortal Wkly Rep 2001:50:162-166.
7. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1365-1371.
8. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecaloccult-blood screening for colorectal cancer. Lancet 1996;348:1472-1477.
9. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecaloccult-blood test. Lancet 1996;348:1467-1471.
10. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999;91:434-437.
11. Young GP, St. John JB, Winawer, SJ, Rozen P. Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies. A WHO and OMED Report. Am J Gastroenterol 2002;97:2499-2507.
12. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996;334:155-159.
13. Winawer SJ, Stewart ET, Zauber AG, Bond JH, Ansel H, Waye JD, et al. A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. National Polyp Study Work Group. N Engl J Med 2000;342:1766-1772.
14. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000;343:1603-1607.
15. Pignone M, Campbell MK, Carr C, Phillips C. Meta-analysis of dietary restriction during fecal occult blood testing. Eff Clin Pract 2001;4:150-156.
16. Sinatra MA, St. John DJ, Young GP. Interference of plant peroxidases with guaiac-based fecal occult blood tests is avoidable. Clin Chem 1999;45:123-126.
17. Rozen P, Knaani J, Samuel Z. Eliminating the need for dietary restrictions when using a sensitive guaiac fecal occult blood test. Dig Dis Sci 1999;44:756-760.
18. Rozen P, Knaani J, Samuel Z. Performance characteristics and comparison of two immunochemical and two guaiac fecal occult blood screening tests for colorectal neoplasia. Dig Dis Sci 1997;42:2064-2071.
19. Bini EJ, Rajapaksa RC, Weinshel EH. The findings and impact of nonrehydrated guaiac examination of the rectum (FINGER) study: a comparison of 2 methods of screening for colorectal cancer in asymptomatic average-risk patients. Arch Intern Med 1999;159:2022-2026.
20. Imperiale TF, Wagner MS, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Results of screening colonoscopy among persons 40 to 49 years of age. N Engl J Med 2002;346:1781-1785.
21. Lurie JD, Welch HG. Diagnostic testing following fecal occult blood screening in the elderly. J Natl Cancer Inst 1999;91:1641-1646.
22. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992;326:653-657.
23. Newcomb PA, Norfleet RG, Storer BE, Surawicz T, Marcus PM. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992;84:1572-1575.
24. Muller AD, Sonnenberg A. Protection by endoscopy against death from colorectal cancer. A case-control study among veterans. Arch Intern Med 1995;155:1741-1748.
25. Kavanagh AM, Giovannucci EL, Fuchs CS, Colditz GA. Screening endoscopy and risk of colorectal cancer in United States men. Cancer Causes Control 1998;9:455-462.
26. Rex DK, Cummings OW, Helper DJ, Nowak TV, McGill JM, Chiao GZ, et al. Five-year incidence of adenomas after negative colonoscopy in asymptomatic average-risk persons. Gastroenterology 1996;111:1178-1181.
27. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329:1977-1981.
28. Levin TR, Palitz A, Grossman S, Conell C, Finkler L, Ackerson L, et al. Predicting advanced proximal colonic neoplasia with screening sigmoidoscopy. JAMA 1999;281:1611-1617.
29. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000;343:162-168.
30. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 2000;343:169-174.
31. Farraye FA, Wallace M. Clinical significance of small polyps found during screening with flexible sigmoidoscopy. Gastrointest Endosc Clin N Am 2002;12:41-51.
32. Thiis-Evensen E, Hoff GS, Sauer J, Langmark F, et al. Populationbased surveillance by colonoscopy: effect on the incidence of colorectal cancer. Scand J Gastroenterol 1999;34:414-420.
33. Atkin WS, Crook CF, Cuzick J, et al. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 2002;359:1291-1300.
34. Hawkins NJ, Ward RL. Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. J Natl Cancer Inst 2001;93:1307-1313.
35. Jass JR. Hyperplastic polyps of the colorectum-innocent or guilty? Dis Colon Rectum 2001;44:163-166.
36. Leggett BA, Devereaux B, Biden K, Searle J, Young J, Jass J. Hyperplastic polyposis: association with colorectal cancer. Am J Surg Pathol 2001;25:177-184.
37. Jorgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 2002;50:29-32.
38. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. Effect of fecal occult blood testing on mortality from colorectal cancer. A case-control study. Ann Intern Med 1993;118:1-6.
39. Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst 1993;85:1311-1318.
40. Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001;345:555-560.
41. Berry DP, Clarke P, Hardcastle JD, Vellacott KD. Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening. Br J Surg 1997;84:1274-1276.
42. Rasmussen M, Kronborg O, Fenger C, Jorgensen OD. Possible advantages and drawbacks of adding flexible sigmoidoscopy to hemoccult-II in screening for colorectal cancer. A randomized study. Scand J Gastroenterol 1999;34:73-78.
43. Citarda F, Tomaselli G, Capocaccia R, Barcherini S, Crespi M. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut 2001;48:812-815.
44. Hofstad B, Vatn M. Growth rate of colon polyps and cancer. Gastrointest Endosc Clin N Am 1997;7:345-363.
45. Rex DK, Cutler CS, Lemmel GT, Rahmani EY, Clark DW, Helper DJ, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997;112:24-28.
46. Rex DK, Chak A, Vasudeva R, Gross T, Lieberman D, Bhattacharya I, et al. Prospective determination of distal colon findings in average-risk patients with proximal colon cancer. Gastrointest Endosc 1999:49:727-730.
47. Rembacken BJ, Fujii T, Cairns A, Dixon MF, Yoshida S, Chalmers DM, et al. Flat and depressed colonic neoplasms: a prospective study of 1000 colonoscopies in the UK. Lancet 2000;355:1211-1214.
48. Saitoh Y, Waxman I, West AB, Popnikolov NK, Gatalica Z, Watari J, et al. Prevalence and distinctive biologic features of flat colorectal adenomas in a North American population. Gastroenterology 2001;120:1657-1665.
49. Scheitel SM, Ahlquist DA, Wollan PC, Hagen PT, Silverstein MD. Colorectal cancer screening: a community case-control study of proctosigmoidoscopy, barium enema radiography, and fecal occult blood test efficacy. Mayo Clin Proc 1999;74:1207-1213.
50. Rex DK, Rahmani EY, Haseman JH, Lemmel GT, Kaster S, Buckley JS. Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice. Gastroenterology 1997;112:17-23.
51. Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer. N Engl J Med 1994;331:1669-1674.
52. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343:78-85.
53. Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 2001;96:2992-3003.
54. Slattery ML, Kerber RA. Family history of cancer and colon cancer risk: the Utah Population Database. J Natl Cancer Inst 1994;86:1618-1626.
55. Houlston RS, Tomlinson IP. Polymorphisms and colorectal tumor risk. Gastroenterology 2001;121:282-301.
56. Pasche B, Kolachana P, Nafa K, Satagopan J, Chen YG, Lo RS, et al. TbetaR-I(6A) is a candidate tumor susceptibility allele. Cancer Res 1999;59:5678-5682.
57. Giardiello FM, Brensinger JD, Luce MC, Petersen GM, Cayouette MC, Krush AJ, et al. Phenotypic expression of disease in families that have mutations in the 5′ region of the adenomatous polyposis coli gene. Ann Intern Med 1997;126:514-519.
58. Brensinger JD, Laken SJ, Luce MC, Powell SM, Vance GH, Ahnen DJ, et al. Variable phenotype of familial adenomatous polyposis in pedigrees with 3′ mutation in the APC gene. Gut 1998;43:548-552.
59. Gardner RJ, Kool D, Edkins E, Walpole IR, Macrae FA, Nasioulas S, et al. The clinical correlates of a 3′ truncating mutation (codons 1982-1983) in the adenomatous polyposis coli gene. Gastroenterology 1997;113:326-331.
60. Soravia C, Berk T, Madlensky L, Mitri A, Cheng H, Gallinger S, et al. Genotype-phenotype correlations in attenuated adenomatous polyposis coli. Am J Hum Genet 1998;62:1290-1301.
61. Heiskanen I, Luostarinen T, Jarvinen HJ. Impact of screening examinations on survival in familial adenomatous polyposis. Scand J Gastroenterol 2000;35:1284-1287.
62. Li G, Tamura K, Yamamoto Y, Sashio H, Utsunomiya J, Yamamura T, et al. Molecular and clinical study of familial adenomatous polyposis for genetic testing and management. J Exp Clin Cancer Res 1999;18:519-529.
63. Giardiello FM, Brensinger JD, Petersen GM, Luce MC, Hylind LM, Bacon JA, et al. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med 1997;336:823-827.
64. Berk T, Cohen Z, Bapat B, Gallinger S. Negative genetic test result in familial adenomatous polyposis: clinical screening implications. Dis Colon Rectum 1999;42:307-310.
65. Winawer SJ, Zauber AG, O'Brien MJ, Ho MN, Gottlieb L, Sternberg SS, et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl J Med 1993;328:901-906.
66. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116:1453-1456.
67. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991;34:424-425.
68. Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997;89:1758-1762.
69. Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000;118:829-834.
70. Samowitz WS, Curtin K, Lin HH, Robertson MA, Schaffer D, Nichols M, et al. The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. Gastroenterology 2001;121:830-838.
71. Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998;338:1481-1487.
72. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, De La Chapelle A, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999;81:214-218.
73. Giardiello FM, Brensinger JD, Petersen GM. AGA medical position statement and technical review on hereditary colorectal cancer and genetic testing. Gastroenterology 2001;121:195-213.
74. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-5257.
75. Loukola A, Eklin K, Laiho P, Salovaara R, Kristo P, Jarvinen H, et al. Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC). Cancer Res 2001;61:4545-4549.
76. Noshirwani KC, van Stolk RU, Rybicki LA, Beck GJ. Adenoma size and number are predictive of adenoma recurrence: implications for surveillance colonoscopy. Gastrointest Endosc 2000;51:433-437.
77. Cali RL, Pitsch RM, Thorson AG, Watson P, Tapia P, Blatchford GJ, et al. Cumulative incidence of metachronous colorectal cancer. Dis Colon Rectum 1993;6:388-393.
78. Jahn H, Joergensen OD, Kronborg O, Fenger C. Can Hemoccult-II replace colonoscopy in surveillance after radical surgery for colorectal cancer and after polypectomy? Dis Colon Rectum 1992;35:253-256.
79. Green RJ, Metlay JP, Propert K, Catalano PJ, Macdonald JS, Mayer RJ, et al. Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med 2002;136:261-269.
80. Schoemaker D, Black R, Giles L, Toouli J. Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. Gastroenterology 1998;114:7-14.
81. Choi PM, Nugent FW, Schoetz DJJ, Silverman ML, Haggitt RC. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 1993;105:418-424.
82. Eaden JA, Ward BA, Mayberry JF. How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance. Gastrointest Endosc 2000;51:123-128.
83. Bernstein CN, Weinstein WM, Levine DS, Shanahan F. Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. Am J GE 1995;90:2106-2114.
84. Engelsgjerd M, Farraye FA, Odze RD. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology 1999;117:1288-1294.
85. Rubin PH, Friedman S, Harpaz N, Goldstein E, Weiser J, Schiller J, et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology 1999;117:1295-1300.
86. Provenzale D, Onken J. Surveillance issues in inflammatory bowel disease: ulcerative colitis. J Clin Gastroenterol 2001;32:99-105.
87. Fenlon HM, Nunes DP, Schroy PC, Barish MA, Clarke PD, Ferrucci JT. A comparison of virtual and conventional colonoscopy for the detection of colorectal polyps. N Engl J Med 1999;341:1496-1503.
88. Yee J, Akerkar GA, Hung RK, Steinauer-Gebauer AM, Wall SD, McQuaid KR. Colorectal neoplasia: performance characteristics of CT colonography for detection in 300 patients. Radiology 2001;219:685-692.
89. Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000;119:1219-1227.
90. Dong SM, Traverso G, Johnson C, Geng L, Favis R, Boynton K, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001;93:858-865.
91. Traverso G, Shuber A, Levin B, Johnson C, Olsson L, Schoetz DJJ, et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002;346:311-320.
92. Traverso G, Shuber A, Olsson L, Levin B, Johnson C, Hamilton SR, et al. Detection of proximal colorectal cancers through analysis of faecal DNA. Lancet 2002;359:403-404.
93. Deber RB. Shared decision making in the real world. J Gen Intern Med 1996;11:377-378.
94. Wood MC, Ryan CT. Resources on colorectal cancer. Cancer Practice 2000;8:308-310.
95. Thiis-Evensen E, Wilhelmsen I, Hoff GS, Blomhoff S, Sauar J. The psychologic effect of attending a screening program for colorectal polyps. Scand J Gastroenterol 1999;34:103-109.
96. Wagner JL, Tunis S, Brown M, Ching A, Almeida R. Cost-effectiveness of colorectal cancer screening in average-risk adults. In: Young G, Levin B, eds. Prevention and early detection of colorectal cancer. London: Saunders, 1996.
97. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000;284:1954-1961.
98. Loeve F, Brown ML, Boer R, van Ballegooijen M, van Oortmarssen GJ, Habbema JD. Endoscopic colorectal cancer screening: a cost-saving analysis. J Natl Cancer Inst 2000;92:557-563.
99. Sonnenberg A, Delco F, Inadomi JM. Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 2000;133:573-584.
100. Coffield AB, Maciosek MV, McGinnis JM, Harris JR, Caldwell MB, Teutsch SM, et al. Priorities among recommended clinical preventive services. Am J Prev Med 2001;21:1-9.
101. Burt RW. Colon cancer screening. Gastroenterology 2000;119:837-853.
102. Raedle J, Trojan J, Brieger A, Weber N, et al. Bethesda Guidelines: relation to microsatellite instability and MLH1 promoter methylation in patients with colorectal cancer. Ann Intern Med 2001;135:566-576.